Instaryl LS Expectorant is a combination pharmaceutical formulation containing Levosalbutamol (1mg/5ml), Ambroxol (30mg/5ml), and Guaifenesin (50mg/5ml), designed to provide effective relief from respiratory conditions characterized by bronchospasm and excessive mucus production. Levosalbutamol, a selective β2-adrenergic receptor agonist, acts as a bronchodilator by relaxing bronchial smooth muscles, thereby improving airflow and alleviating symptoms of bronchoconstriction such as wheezing and shortness of breath. Ambroxol serves as a mucolytic agent, facilitating the breakdown and clearance of viscous mucus in the respiratory tract, enhancing mucociliary transport and promoting expectoration. Guaifenesin functions as an expectorant, increasing respiratory tract fluid secretions to loosen phlegm and reduce cough intensity, aiding in the effective clearance of mucus. The synergistic action of these three active ingredients makes Instaryl LS Expectorant suitable for the management of acute and chronic respiratory disorders including bronchitis, asthma exacerbations, and other conditions involving productive cough with bronchospasm. It is recommended to be used under medical supervision, with dosage adjustments based on patient response and clinical condition. Caution is advised in patients with hypersensitivity to any component, cardiovascular disorders, or hyperthyroidism.